Expectant management surveillance for patients at risk for invasive squamous cell carcinoma of the anus: a large US healthcare system experience
- 79 Downloads
To determine the impact of expectant management surveillance for patients at risk for squamous cell carcinoma of the anus (SCCA).
Adult patients at risk for anal cancer, specifically those with human immunodeficiency virus (HIV) or known human papilloma virus (HPV) infections (anal dysplasia, anogenital warts, cervical dysplasia, or cervical cancer), underwent expectant management surveillance with targeted therapy of only grossly abnormal or symptomatic anoderm lesions. A retrospective analysis investigated the SCCA incidence in these surveilled populations and in the general population patients without known HIV or HPV infection.
There were 452 incident SCCA in a population of 5,978,510 patients (mean follow-up per patient of 5.4 years). Four hundred ten cancers (90.7%) developed in 5,750,501 HIV-negative patients without documented history of HPV infection (cumulative incidence 0.007%). In at-risk patient populations, the cumulative incidence was 0.69% in patients with anal dysplasia (6 out of 872 patients), 0.14% in HIV+ patients (8 out of 5626 patients), and less than 0.1% in the remaining at-risk groups: cervical cancer (1 out of 1168 patients), cervical dysplasia (14 out of 125,604 patients), and genital warts (14 out of 94,739 patients).
Expectant management surveillance, with targeted treatment for symptomatic or abnormal lesions, is an effective strategy for the diagnosis of anal cancer in at-risk patient populations. In this study, most patients who developed anal cancer had no known risk factors. A screening strategy for the general population needs to be further delineated.
KeywordsAnal cancer HIV HPV Anal intraepithelial neoplasia Expectant management
The authors would like to thank Michael Batech and Su-Jau Yang for their support in data collection and statistical analysis.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Cachay ER, Mathews WC (2013) Human papillomavirus, anal cancer, and screening considerations among HIV-infected individuals. AIDS Rev 15(2):122–133Google Scholar
- 3.Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EIO (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365:1576–1585CrossRefGoogle Scholar
- 5.National Cancer Institute: Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/anus. Updated 2018. Accessed August 6, 2018
- 6.May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post F, Fisher M, Ainsworth J, Jose S, Leen C, Nelson M, Anderson J, Sabin C (2014) Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 28(8):1193–1202CrossRefGoogle Scholar
- 8.Saslow D, Solomon D, Lawson HW et al (2012) American Cancer Society, American Society of Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62(3):147–172CrossRefGoogle Scholar
- 14.Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, Hillman RJ, Petoumenos K, Roberts J, Tabrizi SN, Templeton DJ, Grulich AE (2012) Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 13:487–500CrossRefGoogle Scholar
- 26.http://www.cancer-rates.info/ca/ Data from 2005 through 2015. Accessed August 6, 2018
- 28.Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM (2000) Treatment options for perianal Bowen’s disease: survey of ASCRS members. Am Surg 66(7):686–688Google Scholar
- 34.Singh JC, Kuohung V, Palefsky JM (2009) Efficacy of trichloroacetic acid in the treatment of AIN in HIV-positive and HIV-negative MSM. JAIDS 52:474–479Google Scholar
- 35.Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf, and Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of AIN in HIV-positive MSM. Lancet Oncol 2013; 14: 346–353Google Scholar
- 37.Goldstone RN, Hasan SR, Drury S, Darragh TM, van Zante A, and Goldstone SE. A trial of radiofrequency ablation for AIN. Int J Color Dis 2017; 32: 357–365Google Scholar
- 38.Kulasingam S, Havrilesky L, Ghebre R, et al. Screening for cervical cancer: a decision analysis for the US preventive services task force. Agency for Healthcare Research and Quality, Pub No. 11–05157-EF-1. May 2011Google Scholar